Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2019	Nov. 06, 2019
Schedule Of Warrants Activities Used In Derivative Liability [Table Text Block]
Entity Registrant Name	Xtant Medical Holdings, Inc.
Entity Central Index Key	0001453593
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		13,161,762
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 5,749	$ 6,797
Trade accounts receivable, net of allowance for doubtful accounts of $1,375 and $2,140, respectively	9,121	9,990
Inventories	16,025	17,301
Prepaid and other current assets	714	589
Total current assets	31,609	34,677
Property and equipment, net	5,068	7,174
Right-of-use asset, net	2,198
Goodwill	3,205	3,205
Intangible assets, net	529	573
Other assets	428	793
Total Assets	43,037	46,422
Current Liabilities:
Accounts payable	2,249	6,465
Accrued liabilities	6,196	5,150
Warrant derivative liability	17	10
Current portion of lease liability	387
Current portion of financing lease obligations	229	426
Total current liabilities	9,078	12,051
Long-term Liabilities:
Lease liability, less current portion	1,827
Financing lease obligation, less current portion	6	204
Long-term debt, less issuance costs	74,985	77,939
Total Liabilities	85,896	90,194
Commitments and Contingencies (note 10)
Stockholders' Equity (Deficit):
Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.000001 par value; 50,000,000 shares authorized; 13,161,762 shares issued and outstanding as of September 30, 2019 and 13,172,179 shares issued and outstanding as of December 31, 2018
Additional paid-in capital	178,802	171,273
Accumulated deficit	(221,661)	(215,045)
Total Stockholders' Equity (Deficit)	(42,859)	(43,772)
Total Liabilities & Stockholders' Equity (Deficit)	$ 43,037	$ 46,422

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Trade accounts receivable, allowance for doubtful accounts	$ 1,375	$ 2,140
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	13,161,762	13,172,179
Common Stock, shares outstanding	13,161,762	13,172,179

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue
Orthopedic product sales	$ 15,691	$ 17,139	$ 47,574	$ 53,622
Other revenue	30	127	144	319
Total Revenue	15,721	17,266	47,718	53,941
Cost of sales	5,249	5,743	16,527	17,711
Gross Profit	10,472	11,523	31,191	36,230
Operating Expenses
General and administrative	4,155	3,121	12,513	10,006
Sales and marketing	6,682	7,847	19,496	24,742
Research and development	203	347	675	1,179
Depreciation and amortization	137	1,029	442	3,074
Restructuring expenses		614		2,582
Total Operating Expenses	11,177	12,958	33,126	41,583
Loss from Operations	(705)	(1,435)	(1,935)	(5,353)
Other (Expense) Income
Interest expense	(1,185)	(1,790)	(4,504)	(8,156)
Change in warrant derivative liability	4	42	(8)	83
Other (expense) income	30	30	(101)	18
Total Other (Expense)	(1,151)	(1,718)	(4,613)	(8,055)
Net Loss Before Provision for Income Taxes	(1,856)	(3,153)	(6,548)	(13,408)
Provision for income taxes	(23)		(68)
Net Loss	$ (1,879)	$ (3,153)	$ (6,616)	$ (13,408)
Net loss per share:
Basic	$ (0.14)	$ (0.24)	$ (0.50)	$ (1.19)
Dilutive	$ (0.14)	$ (0.24)	$ (0.50)	$ (1.19)
Shares used in the computation:
Basic	13,161,762	13,158,326	13,164,694	11,262,642
Dilutive	13,161,762	13,158,326	13,164,694	11,262,642

Condensed Consolidated Statements of Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Retained Deficit [Member]	Total
Beginning Balance at Dec. 31, 2017		$ 86,247	$ (144,945)	$ (58,698)
Beginning Balance, Shares at Dec. 31, 2017	1,514,899
Stock-based compensation		$ 448		$ 448
Issuance of common stock		$ 79,199		$ 79,199
Issuance of common stock, Shares	11,656,448
Issuance of warrant		$ 5,114		$ 5,114
Net loss			(13,408)	(13,408)
Ending Balance at Sep. 30, 2018		171,008	(158,353)	12,655
Ending Balance, Shares at Sep. 30, 2018	13,171,347
Beginning Balance at Jun. 30, 2018		$ 165,809	$ (155,200)	$ 10,609
Beginning Balance, Shares at Jun. 30, 2018	13,145,305
Stock-based compensation		$ 85		$ 85
Issuance of common stock
Issuance of common stock, Shares	26,042
Issuance of warrant		$ 5,114		$ 5,114
Net loss			(3,153)	(3,153)
Ending Balance at Sep. 30, 2018		171,008	(158,353)	12,655
Ending Balance, Shares at Sep. 30, 2018	13,171,347
Beginning Balance at Dec. 31, 2018		$ 171,273	$ (215,045)	(43,772)
Beginning Balance, Shares at Dec. 31, 2018	13,172,179
Stock-based compensation		$ 256		256
Forfeiture of restricted stock
Forfeiture of restricted stock, shares	(10,417)
Debt extinguishment		$ 7,264		$ 7,264
Issuance of warrant		9		9
Net loss			(6,616)	(6,616)
Ending Balance at Sep. 30, 2019		178,802	(221,661)	(42,859)
Ending Balance, Shares at Sep. 30, 2019	13,161,762
Beginning Balance at Jun. 30, 2019		$ 178,707	$ (219,782)	$ (41,075)
Beginning Balance, Shares at Jun. 30, 2019	13,161,762
Stock-based compensation		$ 95		$ 95
Net loss			(1,879)	(1,879)
Ending Balance at Sep. 30, 2019		$ 178,802	$ (221,661)	$ (42,859)
Ending Balance, Shares at Sep. 30, 2019	13,161,762

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Operating activities:
Net loss	$ (6,616)	$ (13,408)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	2,338	4,943
Gain on disposal of fixed assets	(27)	(15)
Non-cash interest	4,467	7,853
Non-cash rent	16
Non-cash stock option expense/change in derivative warrant liability	263	502
Provision for losses on accounts receivable and inventory	970	298
Changes in operating assets and liabilities:
Accounts receivable	417	2,842
Inventories	760	(508)
Prepaid and other assets	240	1,138
Accounts payable	(4,216)	(3,557)
Accrued liabilities	1,046	(867)
Net cash used in operating activities	(342)	(779)
Investing activities:
Purchases of property and equipment and intangible assets	(403)	(308)
Proceeds from sale of fixed assets	241	251
Net cash used in investing activities	(162)	(57)
Financing activities:
Payments on financing leases	(395)	(260)
Costs associated with Second Amended and Restated Credit Agreement	(149)
Costs associated with private placement and convertible debt conversion/exchange		(3,507)
Proceeds from equity private placement		6,810
Proceeds from issuance of stock		1
Net cash (used in) provided by financing activities	(544)	3,044
Net change in cash and cash equivalents	(1,048)	2,208
Cash and cash equivalents at beginning of period	6,797	2,856
Cash and cash equivalents at end of period	$ 5,749	$ 5,064

Business Description, Basis of Presentation and Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Business Description, Basis of Presentation and Summary of Significant Accounting Policies

(1)

Business Description, Basis of Presentation and Summary of Significant Accounting Policies

Business Description and Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of Xtant Medical Holdings, Inc. (“Xtant”), a Delaware corporation, and its wholly owned subsidiaries, Xtant Medical, Inc. (“Xtant Medical”), a Delaware corporation, Bacterin International, Inc. (“Bacterin”), a Nevada corporation, and X-spine Systems, Inc. (“X-spine”), an Ohio corporation (Xtant, Xtant Medical, Bacterin, and X-spine are jointly referred to herein as the “Company” or sometimes “we”, “our,” or “us”). All intercompany balances and transactions have been eliminated in consolidation.

Xtant is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures.

The accompanying condensed consolidated financial statements of Xtant for the three and nine months ended September 30, 2019 and 2018 are unaudited and are prepared in accordance with accounting principles generally accepted in the United States of America. They do not include all disclosures required by generally accepted accounting principles for annual consolidated financial statements, but in the opinion of management, include all adjustments, consisting only of normal recurring items, necessary for a fair presentation. Certain prior year amounts have been reclassified to conform with current year presentation.

Interim results are not necessarily indicative of results that may be achieved in the future for the full year ending December 31, 2019.

These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto, which are included in Xtant’s Annual Report on Form 10-K for the year ended December 31, 2018. The accounting policies set forth in those annual consolidated financial statements are the same as the accounting policies utilized in the preparation of these condensed consolidated financial statements, except as modified for appropriate interim consolidated financial statement presentation.

As described in more detail below, effective as of February 13, 2018, the Company effected a 1-for-12 reverse split of its common stock (the “Reverse Stock Split”). The Reverse Stock Split is reflected in the share amounts in all periods presented in this report.

Corporate Restructuring

Restructuring Agreement

On January 11, 2018, we entered into a Restructuring and Exchange Agreement (the “Restructuring Agreement”) with ROS Acquisition Offshore LP, OrbiMed Royalty Opportunities II, LP (collectively referred to herein as the “Investors”), Bruce Fund, Inc., Park West Partners International, Limited (“PWPI”), Park West Investors Master Fund, Limited (“PWIMF”), and Telemetry Securities, L.L.C., collectively referred to herein as the “Holders.”

Pursuant to the Restructuring Agreement, and following the execution of the Sixth Amendment to the 2017 Notes, described in the “Debt” and “Equity” sections below, on January 17, 2018, the Investors converted 6.00% convertible senior unsecured notes due 2021, plus accrued and unpaid interest, at the $9.11 per share conversion rate originally provided thereunder (the “2017 Notes”), into 189,645 shares of our common stock.

On February 14, 2018, after giving effect to the Reverse Stock Split (described below), the $70.3 million aggregate principal amount of our then outstanding 6.00% convertible senior unsecured notes due 2021 held by the Holders (the “Remaining Notes”), plus accrued and unpaid interest, were exchanged for newly-issued shares of our common stock at an exchange rate of 138.8889 shares per $1,000 principal amount of the Remaining Notes, for an exchange price of $7.20 per share (the “Notes Exchange”). This resulted in the issuance of 10,401,309 shares of our common stock to the Holders and the Investors acquiring an approximately 70% controlling interest in our outstanding shares of common stock. Upon the completion of the Notes Exchange, all outstanding obligations under our convertible senior secured notes were satisfied in full, and the Indentures governing such notes were discharged.

Pursuant to the terms of the Restructuring Agreement, we commenced a rights offering to allow our stockholders as of a record date of April 27, 2018 to purchase up to an aggregate of 1,137,515 shares of our common stock at a subscription price of $7.20 per share. The rights offering expired on June 18, 2018. We issued 129 shares of common stock in the rights offering and received $0.9 thousand gross proceeds.

Amended and Restated Certificate of Incorporation

On February 13, 2018, following a special meeting of our stockholders, we filed with the Secretary of State of the State of Delaware a Certificate of Amendment to our Certificate of Incorporation (the “Certificate Amendment”). The Certificate Amendment amended and restated our Certificate of Incorporation (the “Charter”) to, among other things:

	●	effect the Reverse Stock Split;
	●	after giving effect to the Reverse Stock Split, decrease the number of authorized shares of common stock available for issuance from 95,000,000 to 50,000,000 and increase the number of authorized shares of preferred stock available for issuance from 5,000,000 to 10,000,000;
	●	authorize the Board of Directors (“Board”) to increase or decrease the number of shares of any series of our capital stock, provided that such increase or decrease does not exceed the number of authorized shares or represent less than the number of shares then outstanding;
	●	authorize the Board to issue new series of preferred stock without approval of the holders of common stock or other series of preferred stock, with such powers, preferences, and rights as may be determined by the Board;
	●	authorize a majority of the Board to fix the number of our directors;
	●	indemnify the members of the Board to the fullest extent permitted by law;
	●	remove the classification of the Board to require all directors to be elected annually;
	●	provide that special meetings of our stockholders may only be called by the Board, the chairman of the Board, or our chief executive officer;
	●	provide that no stockholder will be permitted cumulative voting at any election of directors;
	●	elect not to be governed by Section 203 of the Delaware General Corporation Law (the “DGCL”);
	●	elect the Court of Chancery of the State of Delaware to be the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of a fiduciary duty owed by any of our directors, officers, or other employees, any action under the DGCL, our Charter, or bylaws, or any actions governed by the internal affairs doctrine; and
	●	require the vote of at least two-thirds of the voting power of the then outstanding shares of our capital stock to amend or repeal certain provisions of our Charter.

The Reverse Stock Split became effective as of 5:00 p.m. Eastern Time on February 13, 2018, and our common stock began trading on a split-adjusted basis when the market opened on February 14, 2018. Upon the effectiveness of the Reverse Stock Split, every 12 shares of our issued and outstanding common stock automatically converted into one share of common stock, without any change in the par value per share. In addition, a proportionate adjustment was made to the per share exercise price and the number of shares issuable upon the exercise of all of our outstanding stock options, warrants and convertible securities to purchase shares of common stock and the number of shares underlying restricted stock awards and reserved for issuance pursuant to our equity incentive compensation plan. Any fraction of a share of common stock that would otherwise have resulted from the Reverse Stock Split was rounded down to the nearest whole share. All share and per share amounts have been retroactively restated to reflect the Reverse Stock Split.

Private Placement SPA

On February 14, 2018, we entered into a Securities Purchase Agreement (the “Private Placement SPA”) with the Investors pursuant to which the Investors purchased from us an aggregate of 945,819 shares of our common stock at a price of $7.20 per share for aggregate proceeds of $6.8 million.

Investor Rights Agreement

Effective February 14, 2018, we entered into an Investor Rights Agreement (the “Investor Rights Agreement”) with the Holders. Under the Investor Rights Agreement, the Investors are permitted to nominate a majority of our directors and designate the chairperson of the Board at subsequent annual meetings, as long as the Investors maintain an ownership threshold in the Company of at least 40% of the then outstanding common stock (the “Ownership Threshold”). If the Investors are unable to maintain the Ownership Threshold, the Investor Rights Agreement contemplates a reduction of nomination rights commensurate with their ownership interests.

For so long as the Ownership Threshold is met, we must obtain the approval of the Investors to proceed with the following actions: (i) issue new securities; (ii) incur over $0.25 million of debt in a fiscal year; (iii) sell or transfer over $0.25 million of our assets or businesses or our subsidiaries in a fiscal year; (iv) acquire over $0.25 million of assets or properties in a fiscal year; (v) make capital expenditures over $0.125 million individually or $1.5 million in the aggregate during a fiscal year; (vi) approve our annual budget; (vii) hire or terminate our chief executive officer; (viii) appoint or remove the chairperson of the Board; and (ix) make loans to, make investments in, or purchase, or permit any subsidiary to purchase, any stock or other securities in another entity in excess of $0.25 million in a fiscal year. As long as the Ownership Threshold is met, we may not increase the size of the Board beyond seven directors without the approval of a majority of the directors nominated by the Investors.

The Investor Rights Agreement grants the Holders the right to purchase from us a pro rata amount of any new securities that we may propose to issue and sell. The Investor Rights Agreement may be terminated (a) upon the mutual written agreement of all the parties, (b) upon written notice of the Company or an Investor, if such Investor’s ownership percentage of our then outstanding common stock is less than 10%, or (c) upon written notice by the Investors. PWPI and PWIMF’s right to purchase from us a pro rata amount of any new securities will also terminate at such time as their aggregate ownership percentage of our then outstanding common stock is less than 8.5%.

Registration Rights Agreement

Effective February 14, 2018, we entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the Holders. The Registration Rights Agreement required us to, among other things, file with the U.S. Securities and Exchange Commission (“SEC”) a shelf registration statement within 90 days of the date of the Registration Rights Agreement covering the resale, from time to time, of our common stock issued. The registration statement was filed on May 15, 2018 and became effective on June 4, 2018.

Second Amended and Restated Bylaws

On February 14, 2018, we amended and restated our current bylaws by adopting the Second Amended and Restated Bylaws of the Company (the “Amended Bylaws”). The Amended Bylaws amended our existing bylaws to, among other things:

	●	provide for annual and special meetings of stockholders to be held through remote communications;
	●	provide for the election of any directors not elected at an annual meeting of stockholders to be elected at a special meeting of stockholders;
	●	declassify the Board into one group of directors that will hold office until the subsequent annual meeting of stockholders and until the election and qualification of such directors’ respective successors;
	●	provide for the filling of a new directorship or director vacancy by the affirmative vote of the holders of a majority of the voting power of our shares of stock;

	●	allow for a majority of the Board present to adjourn a Board meeting if a quorum is not met;
	●	unless otherwise restricted in the Amended Bylaws or our Charter, provide the Board with the authority to fix the compensation of directors, including, without limitation, compensation for services as members of Board committees;
	●	allow us to enter into an agreement with a stockholder to restrict the transfer of shares held by such stockholder in any manner not prohibited by the DGCL; and
	●	allow the Board to declare dividends on our capital stock, subject to any provisions of our Charter and applicable law.

Concentrations and Credit Risk

The Company’s accounts receivable are due from a variety of health care organizations and distributors throughout the world. No single customer accounted for more than 10% of revenue or accounts receivable for the comparable periods. The Company provides for uncollectible amounts when specific credit issues arise. Management believes that all significant credit risks have been identified at September 30, 2019.

Use of Estimates

The preparation of the consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the period. Significant estimates include the carrying amount of property and equipment, goodwill and intangible assets and liabilities, valuation allowances for trade receivables, inventory and deferred income tax assets and liabilities, current and long-term financing lease obligations and corresponding right-of-use asset, and estimates for the fair value of long-term debt, stock options and other equity awards upon which the Company determines stock-based compensation expense. Actual results could differ from those estimates.

Long-Lived Assets

Long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. No impairment expense was recorded during the three and nine months ended September 30, 2019.

Goodwill

Goodwill represents the excess of costs over fair value of assets of businesses acquired. Goodwill and intangible assets acquired in a purchase business combination and determined to have indefinite useful lives are not amortized. Instead, they are tested for impairment at least annually, and whenever events or circumstances indicate, the carrying amount of the asset may not be recoverable. No impairment expense was recorded during the three and nine months ended September 30, 2019.

Revenue Recognition

The Company adopted the provisions of Accounting Standards Update (“ASU”) No. 2014-09, Topic 606, Revenue from Contracts with Customers, effective January 1, 2018 (“ASC 606”). This new accounting standard outlines a single, comprehensive model used in accounting for revenue arising from contracts with customers. This standard supersedes existing revenue recognition requirements and eliminates most industry specific guidance from U.S. generally accepted accounting principles (“GAAP”). The core principle of the new accounting standard is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the adoption of this new accounting standard resulted in increased disclosure, including qualitative and quantitative disclosures about the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers.

Disaggregation of Revenue

The Company operates in one reportable segment with our net revenue derived primarily from the sale of orthobiologics and spinal implant products across North America, Europe, Asia Pacific, and Latin America. Sales are reported net of returns. No rebates, group purchasing organization fees, or other customer allowances are present and so are not relevant to net revenue determination. The following table presents revenues from these product lines for the three and nine months ended September 30, 2019 and 2018 (in thousands):

	Three Months Ended		Percentage of			Three Months Ended		Percentage of
	September 30, 2019		Total Revenue			September 30, 2018		Total Revenue
Orthobiologics	$	11,342		72	%	$	11,507		67	%
Spinal implant		4,349		28	%		5,632		33	%
Other revenue		30		0	%		127		0	%
Total revenue	$	15,721		100	%	$	17,266		100	%

	Nine Months Ended		Percentage of			Nine Months Ended		Percentage of
	September 30, 2019		Total Revenue			September 30, 2018		Total Revenue
Orthobiologics	$	34,374		72	%	$	36,419		68	%
Spinal implant		13,200		28	%		17,203		32	%
Other revenue		144		0	%		319		0	%
Total revenue	$	47,718		100	%	$	53,941		100	%

Performance Obligations

The Company’s contracts do not include a right of acceptance or a right to cancel. Therefore, our process for recognizing revenue does not require an evaluation of whether acceptance is received or a right to cancel has expired. Further, the Company does not incur upfront costs or exclusivity fees in conjunction with entering into a customer contract. The Company’s customer contracts do not provide for percentage of completion performance measures or contingent consideration.

In the normal course of business, the Company accepts returns of products that have not been implanted. Product returns are not material to the Company’s consolidated statements of operations. The Company accounts for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. The Company’s policy is to record revenue net of any applicable sales, use, or excise taxes. Payment terms are generally net 30 days from invoice date, and some customers are offered discounts for early pay.

Contract Assets and Liabilities

The Company does not have deferred or unearned revenue arrangements with its customers that would give rise to contract liabilities. The Company recognizes sales commissions as incurred because the amortization period is less than one year. Additionally, the Company does not recognize unbilled receivables or progress payments to be billed that would result in a contract asset. All pricing and agreements are completed based on the contracted individual unit price; no other methods of determining price are allowed within the Company’s sales agreements. Therefore, no contract assets or contract liabilities are recorded in our condensed consolidated balance sheets as of September 30, 2019 and December 31, 2018.

Research and Development

Research and development costs, which are principally related to internal costs for the development of new products, are expensed as incurred.

Net Loss Per Share

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted net income (loss) per share is computed in a manner consistent with that of basic earnings per share while giving effect to all potentially dilutive shares of common stock outstanding during the period, which include the assumed exercise of stock options and warrants using the treasury stock method. Diluted net loss per share was the same as basic net loss per share for the three and nine months ended September 30, 2019 and 2018, as shares issuable upon the exercise of stock options and warrants were anti-dilutive as a result of the net losses incurred for those periods. Dilutive earnings per share are not reported, as the effects of including 3,313,953 and 2,156,882 outstanding stock options, restricted stock units and warrants for the three and nine months ended September 30, 2019 and 2018, respectively, are anti-dilutive.

Fair Value of Financial Instruments

The carrying values of financial instruments, including trade accounts receivable, accounts payable, accrued liabilities, and long-term debt, approximate their fair values based on terms and related interest rates.

The Company follows a framework for measuring fair value. The framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described as follows:

Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.

Level 2: Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. During the nine months ended September 30, 2019 and 2018, there were no reclassifications in financial assets or liabilities between Level 1, 2, or 3 categories.

The following table sets forth by level, within the fair value hierarchy, our liabilities that are measured at fair value on a recurring basis.

Warrant derivative liability (in thousands):

	As of September 30, 2019		As of December 31, 2018
Level 1		—		—
Level 2		—		—
Level 3	$	17	$	10

The valuation technique used to measure fair value of the warrant liability is based on a lattice valuation model and significant assumptions and inputs determined by us. See Note 9, “Warrants,” below.

Recent Accounting Pronouncements

In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial Instruments–Credit Losses: Measurement of Credit Losses on Financial Instruments, which amends certain provisions of ASC 326, Financial Instruments–Credit Loss. The ASU changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held to maturity debt securities, loans, and other instruments, entities will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. In May 2019, the FASB issued ASU No. 2019-05, Financial Instruments–Credit Losses (Topic 326): Targeted Transition Relief. The amendments in the update provide an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. The effective date and transition methodology for the amendment have not changed. The ASU is effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual periods, and will be applied as a cumulative effect adjustment to retained earnings as of the beginning of the first reporting period for which the guidance is effective. We are currently evaluating this update to determine the full impact of its adoption but do not expect the adoption of these provisions will have a material effect on our consolidated financial position, results of operations, or cash flows.

In August 2018, the FASB issued ASU No. 2018-15, Intangibles–Goodwill and Other–Internal-Use Software (Subtopic 350-40), to simplify the accounting for goodwill impairment. The update removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The ASU is effective for annual reporting periods beginning after December 15, 2019, but early adoption is permitted. We are currently evaluating this update to determine the full impact of its adoption but do not expect this accounting standards update to have a material impact on our consolidated financial position, results of operations, or cash flows.

Property and Equipment, Net

9 Months Ended

Sep. 30, 2019

Property, Plant and Equipment [Abstract]

Property and Equipment, Net

(3)

Property and Equipment, Net

Property and equipment, net are as follows (in thousands):

	September 30, 2019			December 31, 2018
Equipment	$	4,140		$	4,145
Computer equipment		455			481
Computer software		570			570
Furniture and fixtures		99			164
Leasehold improvements		3,979			3,941
Vehicles		10			10
Surgical instruments		10,872			10,772
Total cost		20,125			20,083
Less: accumulated depreciation		(15,057	)		(12,909	)
Property and equipment, net	$	5,068		$	7,174

Depreciation expense related to property and equipment, including property under capital lease, for the first nine months of 2019 and 2018 was $2.3 million and $2.4 million, respectively. Depreciation expense not included as part of the depreciation and amortization line item within the condensed consolidated statements of operations is classified as part of cost of sales.

The Company leases certain equipment under finance leases. For financial reporting purposes, minimum lease payments relating to the assets have been capitalized. As of September 30, 2019, the Company has recorded $1.5 million of gross assets in equipment and $0.9 million of accumulated depreciation.

Debt

9 Months Ended

Sep. 30, 2019

Debt Disclosure [Abstract]

Debt

(6)

Debt

Convertible Note Indenture

During the first quarter of 2018 in connection with our Restructuring, all of the outstanding 6.00% convertible senior unsecured notes due 2021 were converted into shares of our common stock and the Indenture governing such notes was discharged.

Twenty-Second Amendment to the Amended and Restated Credit Agreement

Effective January 30, 2018, the Company and the Investors entered into the Twenty-Second Amendment to the Amended and Restated Credit Agreement dated July 27, 2015, which amended the Amended and Restated Credit Agreement by and between Bacterin and ROS Acquisition Offshore LP (collectively, the “Prior Credit Agreement” and the facility created under such agreement, the “Credit Facility”). This amendment further deferred the Company’s accrued interest payment date for the fiscal quarters ended on December 31, 2016, March 31, 2017, June 30, 2017, September 30, 2017, and December 31, 2017, until February 28, 2018.

Twenty-Third Amendment to the Prior Credit Agreement

Effective February 14, 2018, the Company and the Investors entered into the Twenty-Third Amendment to the Prior Credit Agreement, which further amended the Prior Credit Agreement and terms of the Credit Facility. As of this amendment, the interest payable was carried forward. As modified, the interest rate options within the Credit Facility were as follows: (i) through December 31, 2018, we had the option at our sole discretion (a) to pay PIK Interest at LIBOR (as defined in the Credit Facility) plus 12% or (b) pay cash interest at LIBOR plus 10%; (ii) beginning January 1, 2019 through September 30, 2019, we had the option at our sole discretion to either (a) pay PIK Interest at LIBOR plus 15% or (b) pay cash interest at LIBOR plus 10%; and (iii) beginning July 1, 2019 through the maturity date of the Credit Facility, we will pay cash interest at LIBOR plus 10%. The amendment also reduced the prepayment or repayment fee under the Credit Facility to 1%.

This amendment also modified the financial covenants in the Prior Credit Agreement, including removing the minimum revenue covenant and providing a minimum liquidity covenant, a consolidated leverage ratio covenant, and a minimum consolidated EBITDA covenant, all as defined in the Prior Credit Agreement.

Twenty-Fourth Amendment to the Prior Credit Agreement

On September 17, 2018, the Company and the Investors entered into the Twenty-Fourth Amendment to the Prior Credit Agreement (the “24^th Amendment”), which further amended the Prior Credit Agreement and the terms of the Credit Facility, effective as of April 1, 2018. Under the terms of the 24^th Amendment, no interest was charged on the loans under the Credit Facility (the “Loans”) from April 1, 2018, until June 30, 2018.

Due to the interest rate relief provided by the 24^th Amendment, the Company performed an assessment of the changes to the terms of the Credit Facility in accordance with ASC 470, Debt. The Credit Facility was modified based on an evaluation of the present value of cash flows for the old and new debt instruments. Given the modification, a new effective interest rate of 13.45% for the modified loan was calculated based on the carrying amount of the debt and the present value of the revised future cash flows. The modified interest rate is effective through the remaining life of the loan.

Twenty-Fifth Amendment to the Prior Credit Agreement

Also, on September 17, 2018, the Company and the Investors entered into the Twenty-Fifth Amendment to the Prior Credit Agreement (the “25^th Amendment”), which further amended the Prior Credit Agreement and terms of the Credit Facility, effective as of August 1, 2018. Under the terms of the 25^th Amendment:

	●	no interest was charged on the Loans under the Credit Facility from July 1, 2018 until December 31, 2018;
	●	the Optional PIK Interest (as such term is defined in the Prior Credit Agreement) was decreased from 15% plus the LIBO Rate (as such term is defined in the Amended and Restated Credit Agreement) to 10% plus the LIBO Rate, with a 2.3125% floor;
	●	a LIBO Rate floor of 2.3125% was added; and
	●	the fee due upon payment, prepayment, or repayment of the principal amount of the Loans under the Credit Facility, whether on the maturity date or otherwise, was increased to 2% from 1% of the aggregate principal amount of such payment, prepayment, or repayment.

The Company issued warrants to purchase an aggregate of 1.2 million shares of Company common stock to the Investors with an exercise price of $0.01 per share and an expiration date of August 1, 2028 (collectively, the “2018 Warrants”). The issuance of the 2018 Warrants occurred on September 17, 2018 and was a condition to the effectiveness of the 25^th Amendment. See Note 9, “Warrants,” below.

Second Amended and Restated Credit Agreement

On March 29, 2019, the Company and the Investors entered into a Second Amended and Restated Credit Agreement (the “Second Amended and Restated Credit Agreement”), which amended and restated the Prior Credit Agreement. Under the Second Amended and Restated Credit Agreement:

	●	We may continue to make requests for term loans in amounts equal to the remaining commitment for additional delayed draw loans, which was approximately $2.2 million as of the date of the Second Amended and Restated Credit Agreement, and may request additional term loans with the Investors in an aggregate amount of up to $10.0 million, with the amount of each loan draw to be subject to our production of a thirteen-week cash flow forecast that is approved by the Investors and which shows a projected cash balance for the following two-week period of less than $1.5 million, as well as the satisfaction (or waiver in writing by each Investor) of conditions precedent, including closing certificate, delivery of budget, and other satisfactory documents;
	●	no interest will accrue on the Loans under the Second Amended and Restated Credit Agreement from and after January 1, 2019 until March 31, 2020;
	●	beginning April 1, 2020 through the maturity date of the Second Amended and Restated Credit Agreement, interest payable in cash will accrue on the Loans under the Credit Agreement at a rate per annum equal to the sum of (a) 10.00% plus (b) the higher of (x) the LIBO Rate (as such term is defined in the Second Amended and Restated Credit Agreement) and (y) 2.3125%;
	●	the maturity date of the Loans is March 31, 2021;
	●	the Consolidated Senior Leverage Ratio and Consolidated EBITDA (as such terms were defined in the Prior Credit Agreement) financial covenants were deleted, and a new Revenue Base (as such term is defined in the Second Amended and Restated Credit Agreement) financial covenant was added; and
	●	the key person event default provision was revised to refer specifically to certain recently-hired executive officers of the Company.

Long-term debt, less issuance costs consists of long-term debt due to the lenders under our Second Amended and Restated Credit Agreement as of September 30, 2019 and under our Prior Credit Agreement as of December 31, 2018. The execution of the Second Amended and Restated Credit Agreement during the first quarter of 2019 and the changes to our credit facility reflected therein, including the interest rate relief and extended maturity, along with the additional availability, were determined to be and accounted for as a debt extinguishment under GAAP, resulting in the write-off of the original loan and associated issuance costs. The present value of the new loan was determined to be $72.7 million as of March 31, 2019 with the Company recording an increase to additional paid-in capital of $7.3 million. Because of the related party affiliation between the Company and our credit facility lenders, this debt extinguishment resulted in an increase in additional paid-in capital rather than flowing through our condensed consolidated statements of operations as a gain on extinguishment. As of September 30, 2019, our long-term debt, less issuance costs was $75.0 million. Assuming no debt payments are made, our long-term debt, less issuance costs line item will continue to increase until the loan’s March 31, 2021 maturity date.

While our long-term debt, less issuance costs balance was $75.0 million as of September 30, 2019 under GAAP, the Company owes a principal balance of $55.8 million plus accrued PIK interest of $27.2 million as of September 30, 2019.

Due to the terms within the Second Amended and Restated Credit Agreement, the Company performed an assessment of the changes to the terms of the Prior Credit Agreement in accordance with ASC 470. Given there were cumulative changes to the Prior Credit Agreement within one year of March 29, 2019, the debt terms that existed as of March 29, 2018 were used in the evaluation of the present value of cash flows for the old and new debt instruments which resulted in the extinguishment of the Prior Credit Agreement and recognition of the Second Amended and Restated Credit Agreement. A new effective interest rate of 13.19% for the Second Amended and Restated Credit Agreement was calculated based on the carrying amount of the debt and the present value of the revised future cash flows. This rate is effective through the remaining life of the loan.

On April 1, 2019, the Company issued warrants to purchase an aggregate of 1.2 million shares of Company common stock to the Investors, with an exercise price of $0.01 per share and an expiration date of April 1, 2029 (collectively, the “2019 Warrants”). The issuance of the 2019 Warrants occurred on April 1, 2019 and was a condition to the effectiveness of the Second Amended and Restated Credit Agreement.

Long-term debt consists of the following (in thousands):

	September 30, 2019			December 31, 2018
Amounts due under Second Amended and Restated Credit Agreement	$	72,657		$	—
Amounts due under Prior Credit Agreement		—			55,787
PIK interest payable related to Credit Agreements		2,172			27,178
Plus: 2% exit fee on Prior Credit Agreement		266			254
Gross long-term debt		75,095			83,219
Less: discount on Credit Agreements		—			(5,114	)
Less: total debt issuance costs on Credit Agreements		(110	)		(166	)
Long-term debt, less issuance costs	$	74,985		$	77,939

The following is a summary of maturities due on the long-term debt as of September 30, 2019 (in thousands):

Remainder of 2019	$	—
2020		—
2021		75,095
2022		—
2023		—
Thereafter		—
Total	$	75,095

Equity

9 Months Ended

Sep. 30, 2019

Equity [Abstract]

Equity

(7)

Equity

Charter Amendment

On October 30, 2019, the Company’s stockholders, upon recommendation of the Board, approved an amendment to the Company’s Charter to increase the number of authorized shares of common stock from 50,000,000 to 75,000,000.

Convertible Note Indenture

During the first quarter of 2018, in connection with our Restructuring (defined above), all of the outstanding 6.00% convertible senior unsecured notes due 2021 were converted or exchanged into shares of our common stock, and the Indenture governing such notes was discharged. On January 17, 2018, the Investors converted a $1.6 million aggregate principal amount of 6.00% convertible senior unsecured promissory notes due in 2021, which were issued effective January 17, 2017, plus accrued and unpaid interest, into 189,645 shares of our common stock. On February 14, 2018, an additional $70.3 million aggregate principal amount of notes, plus accrued and unpaid interest, were exchanged for 10,401,309 newly-issued shares of our common stock.

Private Placement SPA

On February 14, 2018, we sold to the Investors, pursuant to the Private Placement SPA, 945,819 shares of our common stock at a price of $7.20 per share for aggregate proceeds of $6.8 million.

Registration Rights Agreement

On May 15, 2018, we filed a shelf resale registration statement with the SEC pursuant to our obligations under the Registration Rights Agreement. This registration statement was declared effective by the SEC on June 4, 2018.

Rights Offering

On May 18, 2018, we distributed to holders of our common stock, at no charge, non-transferable subscription rights to purchase up to an aggregate of 1,137,515 shares of our common stock (the “Rights Offering”). In the Rights Offering, holders received 0.0869816 subscription rights for each share of common stock held on the record date, April 27, 2018. The units were priced at $7.20 per unit. The Rights Offering expired on June 18, 2018, at which time the rights were no longer exercisable. We issued 129 shares of our common stock in the Rights Offering, resulting in $0.9 thousand in gross proceeds to us.

Stock-Based Compensation

9 Months Ended

Sep. 30, 2019

Share-based Payment Arrangement [Abstract]

Stock-Based Compensation

(8)

Stock-Based Compensation

Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan

On August 1, 2018, our stockholders approved the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan at the 2018 annual meeting of stockholders of Xtant and at the 2019 annual meeting of stockholders held on October 30, 2019 approved an amendment to increase the number of shares of common stock available thereunder by 1,500,000 shares (as amended, the “2018 Plan”). The 2018 Plan became effective immediately upon initial approval of the plan by our stockholders on August 1, 2018 and will expire on July 31, 2028, unless terminated earlier. The 2018 Plan replaced the Amended and Restated Xtant Medical Equity Incentive Plan (the “Prior Plan”) with respect to future grants of equity awards, although the Prior Plan continues to govern equity awards granted under the Prior Plan. The 2018 Plan permits the Board, or a committee thereof, to grant to eligible employees, non-employee directors, and consultants of the Company non-statutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units, deferred stock units, performance awards, non-employee director awards, and other stock-based awards. The Board may select 2018 Plan participants and determine the nature and amount of awards to be granted. Subject to adjustment as provided in the 2018 Plan, the number of shares of our common stock available for issuance under the 2018 Plan is 2,807,747 shares, of which 1,742,387 shares remain available as of the date of this report. Under the 2018 Plan, shares of our common stock related to awards granted under the plan that terminate by expiration, forfeiture, cancellation, or otherwise without the issuance of the shares become available again for grant under the plan.

The Board has granted various awards under the 2018 Plan to certain directors, officers and employees. As of September 30, 2019, stock options to purchase an aggregate of 210,360 shares of our common stock, a restricted stock award for 13,021 shares of common stock, and restricted stock units covering 129,204 shares were outstanding under the 2018 Plan. During the nine months ended September 30, 2019, options to purchase 420,000 shares of common stock granted under the 2018 Plan were forfeited and cancelled as a result of the termination of employment of optionees. Effective October 7, 2019, the Company entered into an employment agreement with Sean Browne as the Company’s President and Chief Executive Officer. In connection with the employment agreement, the Company granted stock options to purchase 329,044 shares of our common stock and restricted stock units covering 329,044 shares effective as of October 15, 2019.

The Board also granted various awards under the Prior Plan. As of September 30, 2019, stock options to purchase an aggregate of 17,772 shares of our common stock and restricted stock awards for 23,438 shares of our common stock were outstanding under the Prior Plan. During the nine months ended September 30, 2019, options to purchase 3,416 shares of our common stock granted under the Prior Plan were forfeited and cancelled as a result of the termination of employment of optionees and a restricted stock award for 10,417 shares of our common stock was forfeited and cancelled as a result of the termination of service of a director.

From time to time, we have granted options to purchase shares of our common stock outside of any stockholder-approved plan to new hires (collectively the “Non-Plan Grants”). As of September 30, 2019, no Non-Plan Grants were outstanding. During the nine months ended September 30, 2019, Non-Plan Grants to purchase 25,000 shares of common stock were forfeited and cancelled as a result of the termination of employment of the optionee.

Stock options granted under the 2018 Plan may be either incentive stock options to employees, as defined in Section 422A of the Internal Revenue Code of 1986, or non-qualified stock options. The exercise price of all stock options granted under the 2018 Plan must be at least equal to the fair market value of the shares of common stock on the date of the grant. The 2018 Plan is administered by the Board. Stock options granted under the 2018 Plan are generally not transferable, vest in installments over the requisite service period, and are exercisable during the stated contractual term of the option only by the optionee.

Stock-based compensation expense recognized in the consolidated statements of operations for the nine months ended September 30, 2019 and 2018 is based on awards expected to vest and reflects an estimate of awards that will be forfeited. Stock options to purchase an aggregate of 179,590 shares of common stock were issued during the nine months ended September 30, 2019; options to purchase an aggregate of 410,770 shares of common stock were issued during the same period in 2018.

Stock option activity, including options granted under the 2018 Plan, the Prior Plan, and the Non-Plan Grants, was as follows:

	2019							2018
	Shares			Weighted Average Exercise Price Per Share		Weighted Average Fair Value at Grant Date Per Share		Shares			Weighted Average Exercise Price Per Share		Weighted Average Fair Value at Grant Date Per Share
Outstanding at January 1		496,958		$	9.90	$	6.62		67,465		$	71.03	$	36.85
Granted		179,590		$	2.47	$	2.02		410,770		$	5.71	$	3.91
Cancelled or expired		(448,416	)	$	5.51	$	4.21		(33,002	)	$	53.23	$	36.42
Outstanding at September 30		228,132		$	12.51	$	7.64		445,233		$	12.09	$	6.49
Exercisable at September 30		25,464		$	89.03	$	49.36		34,463		$	135.23	$	67.26

The estimated fair value of stock options granted is calculated using the Black-Scholes-Merton method applied to individual grants. Key assumptions used to estimate the fair value of stock awards are as follows:

	Nine Months Ended
	September 30,
	2019			2018
Risk free interest rate		2.2	%		2.9	%
Dividend yield		0	%		0	%
Expected term		8.3 years			10 years
Expected volatility		92	%		90	%

Total stock-based compensation recognized for employees and directors was $0.3 million and $0.6 million for the nine months ended September 30, 2019 and 2018, respectively, and was recognized as general and administrative expense. The aggregate intrinsic value of options outstanding as of September 30, 2019 was $66 thousand.

Warrants

9 Months Ended

Sep. 30, 2019

Warrants and Rights Note Disclosure [Abstract]

Warrants

(9)

Warrants

2019 Warrants

On April 1, 2019, the Company issued warrants to purchase an aggregate of 1.2 million shares of Company common stock to the Investors with an exercise price of $0.01 per share and an expiration date of April 1, 2029. As a result of the issuance of the warrant to purchase 1.2 million shares of common stock on April 1, 2019, the total outstanding common stock warrants as of April 1, 2019 was 2,910,609. The issuance of the 2019 Warrants was a condition to the effectiveness of the Second Amended and Restated Credit Agreement. The fair value of the 2019 Warrants upon issuance was determined to be $9 thousand. The significant decrease in value of the 2019 Warrants compared to the 2018 Warrants was attributable to the updated forecasts and assumptions used by the Company during the annual planning process for 2019 that resulted in our decision to conclude that a goodwill and intangible asset impairment charge was appropriate during the fourth quarter of 2018. The 2019 Warrants meet all the requirements to be classified as equity awards in accordance with ASC No. 815-40. The number of shares of Company common stock issuable upon exercise of the 2019 Warrants is subject to standard and customary anti-dilution provisions for stock splits, stock dividends, or similar transactions.

	Common Stock Warrants		Weighted Average Exercise Price
Outstanding at January 1, 2019		1,710,609	$	7.33
Issued		1,200,000		0.01
Expired		—		—
Outstanding at September 30, 2019		2,910,609	$	4.31

The estimated fair value was derived using a valuation model with the following weighted-average assumptions:

	Nine Months Ended September 30,
	2019			2018
Value of underlying common stock (per share)	$	2.84		$	3.85
Risk free interest rate		1.7	%		2.10	%
Expected term in years		3.0			3.9
Volatility		85	%		62	%
Dividend yield		0	%		0	%

The following table summarizes our activities related to warrants accounted for as a derivative liability for the nine months ended September 30, 2019 and 2018:

	2019		2018
Balance at January 1,		87,509		93,759
Derivative warrants expired		—		(6,250	)
Balance at September 30,		87,509		87,509

We utilize a lattice valuation model to determine the fair market value of the warrants accounted for as liabilities. The lattice valuation model accommodates the probability of exercise price adjustment features, as outlined in the warrant agreements. We recorded an unrealized loss of $8 thousand resulting from the change in the fair value of the warrant derivative liability for the nine months ended September 30, 2019. Under the terms of some of our warrant agreements, at any time while the warrant is outstanding, the exercise price per share can be reduced to the price per share of future subsequent equity sales of our common stock or a common stock equivalent that is lower than the exercise price per share as stated in the warrant agreement.

Commitments and Contingencies

9 Months Ended

Sep. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

(10)

Commitments and Contingencies

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires lessees to recognize a right-of-use (“ROU”) asset and lease liability on their balance sheet for all leases with terms beyond 12 months. The new standard also requires enhanced disclosures intended to provide more transparency and information to financial statement users about lease portfolios. The distinction between operating and finance leases will continue to exist under the new standard. Additionally, the recognition and measurement of operating and finance lease expenses and cash flows will not change significantly from current treatment. For finance leases, lessees will continue to recognize interest expense on the lease liability using the effective yield method, while the right-of-use asset will be amortized on a straight-line basis. For operating leases, expense will be recognized on a straight-line basis, consistent with the previous standard.

Operating Leases

We lease six office facilities as of September 30, 2019. These leases are under non-cancelable operating lease agreements with expiration dates between 2019 and 2025. We have the option to extend certain leases to five or ten-year term(s), and we have the right of first refusal on any sale.

The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its long-term operating leases as right-of-use assets. Upon initial adoption, using the modified retrospective transition approach, no leases with terms less than 12 months have been capitalized to the balance sheet consistent with ASC 842. Instead, these leases are recognized in the condensed consolidated statement of operations on a straight-line expense throughout the lives of the leases. All leases of the Company do not contain common area maintenance or security agreements. In connection with certain operating leases, the Company has security deposits recorded and maintained as a prepaid asset totaling $49 thousand as of September 30, 2019.

We have made certain assumptions and judgments when applying ASC 842, the most significant of which is that we elected the package of practical expedients available for transition, which allow us to not reassess whether expired or existing contracts contain leases under the new definition of a lease, lease classification for expired or existing leases, and whether previously capitalized initial direct costs would qualify for capitalization under ASC 842. Additionally, we did not elect to use hindsight when considering judgments and estimates such as assessments of lessee options to extend or terminate a lease or purchase the underlying asset.

Present Value of Long-term Leases

(in thousands):	September 30, 2019
Right-of-use assets, net	$	2,198

Current portion of lease liability		387
Lease liability, less current portion		1,827
Total lease liability	$	2,214

As of September 30, 2019, the weighted-average remaining lease term was 5 years. The Company’s lease agreements do not provide a readily determinable implicit rate nor is it available to the Company from its lessors. Instead, as of September 30, 2019, the Company estimates the weighted-average discount rate for its operating leases to be 5.2% to present value based on the incremental borrowing rate.

Future minimum payments for the next five years and thereafter as of September 30, 2019 under these long-term operating leases are as follows (in thousands):

Remainder of 2019	$	125
2020		501
2021		507
2022		521
2023		489
Thereafter		404
Total future minimum lease payments		2,547
Less amount representing interest		(333	)
Present value of obligations under operating leases		2,214
Less current portion		(387	)
Long-term operating lease obligations	$	1,827

Rent expense was $0.4 million and $0.9 million for each of the nine months ended September 30, 2019 and 2018, respectively. We have no contingent rent agreements.

Financing Leases

Future minimum payments for the next five years and thereafter as of September 30, 2019 under financing leases for equipment are as follows (in thousands):

Remainder of 2019	$	53
2020		205
2021		—
2022		—
2023		—
Thereafter		—
Total future minimum lease payments		258
Less amount representing interest		(23	)
Present value of obligations under financing leases		235
Less current portion		(229	)
Long-term financing lease obligations	$	6

Litigation

On December 13, 2018, a complaint was filed by RSB Spine, LLC, against Xtant Medical Holdings, Inc., which claims that some of our products, including the Irix-ATM Lumbar Integrated Fusion System and the Irix-CTM Cervical Integrated Fusion System, infringe certain of RSB Spine’s patents. The complaint seeks an adjudication of infringement, an injunction against future infringement, unspecified damages for infringement, a finding that such infringement is willful, and treble damages for such willful infringement. This action was brought in the United States District Court for the District of Delaware. We filed an answer and affirmative defenses to the complaint on March 29, 2019, denying the allegations of infringement and seeking dismissal of RSB Spine’s claims and requested relief. The Court entered a scheduling order on May 9, 2019, scheduling trial for no sooner than June 21, 2021. We intend to vigorously defend the claims in this action. There can be no assurance that the resolution of this matter will not have a material adverse effect on our business, financial condition, or results of operations.

In addition, we are subject to potential liabilities under government regulations and various claims and legal actions that are pending or may be asserted from time to time. These matters arise in the ordinary course and conduct of our business and may include, for example, commercial, product liability, intellectual property, and employment matters. We intend to continue to defend the Company vigorously in such matters and when warranted, take legal action against others. Furthermore, we regularly assess contingencies to determine the degree of probability and range of possible loss for potential accrual in our financial statements.

An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on our assessment, we have adequately accrued an amount for contingent liabilities currently in existence. We do not accrue amounts for liabilities that we do not believe are probable or that we consider immaterial to our overall financial position. Litigation is inherently unpredictable, and unfavorable resolutions could occur. As a result, assessing contingencies is highly subjective and requires judgment about future events. The amount of ultimate loss may exceed the Company’s current accruals, and it is possible that its cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of one or more of these contingencies.

Indemnifications

Our indemnification arrangements generally include limited warranties and certain provisions for indemnifying customers against liabilities if our products or services infringe a third-party’s intellectual property rights. To date, we have not incurred any material costs as a result of such warranties or indemnification provisions and have not accrued any liabilities related to such obligations in the accompanying condensed consolidated financial statements.

We have also agreed to indemnify our directors and executive officers for costs associated with any fees, expenses, judgments, fines, and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by us, arising out of that person’s services as our director or officer or that person’s services provided to any other company or enterprise at our request.

Income Taxes

9 Months Ended

Sep. 30, 2019

Income Tax Disclosure [Abstract]

Income Taxes

(11)

Income Taxes

In evaluating the realizability of the net deferred tax assets, we take into account a number of factors, primarily relating to the ability to generate taxable income. Where it is determined that it is likely that we will be unable to realize deferred tax assets, a valuation allowance is established against the portion of the deferred tax asset. Because it cannot be accurately determined when or if we will become profitable, a valuation allowance was provided against the entire deferred income tax asset balance.

The Company did not recognize any interest or penalties related to income taxes for the nine months ended September 30, 2019 and 2018.

Supplemental Disclosure of Cash Flow Information

9 Months Ended

Sep. 30, 2019

Supplemental Cash Flow Elements [Abstract]

Supplemental Disclosure of Cash Flow Information

(12)

Supplemental Disclosure of Cash Flow Information

Supplemental cash flow information is as follows (in thousands):

	Nine Months Ended
	September 30,
	2019		2018
Supplemental disclosure of cash flow information
Cash paid during the period for:
Interest	$	47	$	170
Non-cash activities:
Issuance of capital leases	$	—	$	84
Lease liability from right-of-use assets	$	2,296	$	—
Interest converted into common stock	$	—	$	556
Conversion of convertible debt to equity	$	—	$	71,865
Convertible PIK interest	$	—	$	4,764
Conversion of interest related to the Credit Facility to long-term debt	$	—	$	7,977
Write-off of convertible debt issuance cost	$	—	$	1,012
Transfer of inventory to property and equipment	$	—	$	448
Extinguishment of Prior Credit Agreement (including debt issuance costs)	$	79,624	$	—
Write-off of Prior Credit Agreement debt issuance costs and existing ROS fees	$	307	$	—
Recognition of Second Amended and Restated Credit Agreement	$	72,657	$	—
Recognition of 2019 Warrants	$	9	$	—
Debt discount	$	—	$	5,114

Related Party Transactions

9 Months Ended

Sep. 30, 2019

Related Party Transactions

(13)

Related Party Transactions

The Investors, owning approximately 70% of the Company’s outstanding common stock, are the sole holders of our outstanding long-term debt. In addition, as described in more detail under Note 1, “Business Description and Summary of Significant Accounting Policies,” we are party to an Investor Rights Agreement and Registration Rights Agreement with the Investors. Transactions between the Company and the Investors are conducted under the provisions of the Second Amended and Restated Credit Agreement, the Prior Credit Agreement, the Investor Rights Agreement, and the Registration Rights Agreement, as noted above.

On April 5, 2019, the Company entered into a Sublease Agreement wherein the Company leases from Cardialen, Inc., a portion of Cardialen’s office space commencing April 2019 on a month-to-month basis until January 2024, unless terminated earlier upon notice of 60 days. The rent was $2,100 per month for the months of April through July 2019 and is currently $1,260 per month. Because Jeffrey Peters is both a member of our Board and the Chief Executive Officer, President, and a Director of Cardialen, this transaction qualifies as a related party transaction.

All related party transactions are reviewed and approved by the Audit Committee or the disinterested members of the full Board.

Segment and Geographic Information

9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Segment and Geographic Information

(14)

Segment and Geographic Information

The Company’s management reviews financial results and manages the business on an aggregate basis. Therefore, financial results are reported in a single operating segment: the development, manufacture, and marketing of orthopedic medical products and devices.

The Company attributes revenues to geographic areas based on the location of the customer. Approximately 96% and 95% of sales were in the United States for the nine months ended September 30, 2019 and 2018, respectively. Total revenue by major geographic area is as follows (in thousands):

	Three Months Ended September 30,
	2019		2018
United States	$	15,097	$	16,496
Rest of world		624		770
Total revenue	$	15,721	$	17,266

	Nine Months Ended September 30,
	2019		2018
United States	$	45,781	$	51,288
Rest of world		1,937		2,653
Total revenue	$	47,718	$	53,941

Business Description, Basis of Presentation and Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Business Description and Basis of Presentation

Business Description and Basis of Presentation

Interim results are not necessarily indicative of results that may be achieved in the future for the full year ending December 31, 2019.

Corporate Restructuring

Corporate Restructuring

Restructuring Agreement

Amended and Restated Certificate of Incorporation

	●	effect the Reverse Stock Split;
	●	after giving effect to the Reverse Stock Split, decrease the number of authorized shares of common stock available for issuance from 95,000,000 to 50,000,000 and increase the number of authorized shares of preferred stock available for issuance from 5,000,000 to 10,000,000;
	●	authorize the Board of Directors (“Board”) to increase or decrease the number of shares of any series of our capital stock, provided that such increase or decrease does not exceed the number of authorized shares or represent less than the number of shares then outstanding;
	●	authorize the Board to issue new series of preferred stock without approval of the holders of common stock or other series of preferred stock, with such powers, preferences, and rights as may be determined by the Board;
	●	authorize a majority of the Board to fix the number of our directors;
	●	indemnify the members of the Board to the fullest extent permitted by law;
	●	remove the classification of the Board to require all directors to be elected annually;
	●	provide that special meetings of our stockholders may only be called by the Board, the chairman of the Board, or our chief executive officer;
	●	provide that no stockholder will be permitted cumulative voting at any election of directors;
	●	elect not to be governed by Section 203 of the Delaware General Corporation Law (the “DGCL”);
	●	elect the Court of Chancery of the State of Delaware to be the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of a fiduciary duty owed by any of our directors, officers, or other employees, any action under the DGCL, our Charter, or bylaws, or any actions governed by the internal affairs doctrine; and
	●	require the vote of at least two-thirds of the voting power of the then outstanding shares of our capital stock to amend or repeal certain provisions of our Charter.

Private Placement SPA

Investor Rights Agreement

Registration Rights Agreement

Second Amended and Restated Bylaws

	●	provide for annual and special meetings of stockholders to be held through remote communications;
	●	provide for the election of any directors not elected at an annual meeting of stockholders to be elected at a special meeting of stockholders;
	●	declassify the Board into one group of directors that will hold office until the subsequent annual meeting of stockholders and until the election and qualification of such directors’ respective successors;
	●	provide for the filling of a new directorship or director vacancy by the affirmative vote of the holders of a majority of the voting power of our shares of stock;

	●	allow for a majority of the Board present to adjourn a Board meeting if a quorum is not met;
	●	unless otherwise restricted in the Amended Bylaws or our Charter, provide the Board with the authority to fix the compensation of directors, including, without limitation, compensation for services as members of Board committees;
	●	allow us to enter into an agreement with a stockholder to restrict the transfer of shares held by such stockholder in any manner not prohibited by the DGCL; and
	●	allow the Board to declare dividends on our capital stock, subject to any provisions of our Charter and applicable law.

Concentrations and Credit Risk

Concentrations and Credit Risk

Use of Estimates

Use of Estimates

Long-Lived Assets

Long-Lived Assets

Goodwill

Goodwill

Revenue Recognition

Revenue Recognition

Disaggregation of Revenue

	Three Months Ended		Percentage of			Three Months Ended		Percentage of
	September 30, 2019		Total Revenue			September 30, 2018		Total Revenue
Orthobiologics	$	11,342		72	%	$	11,507		67	%
Spinal implant		4,349		28	%		5,632		33	%
Other revenue		30		0	%		127		0	%
Total revenue	$	15,721		100	%	$	17,266		100	%

	Nine Months Ended		Percentage of			Nine Months Ended		Percentage of
	September 30, 2019		Total Revenue			September 30, 2018		Total Revenue
Orthobiologics	$	34,374		72	%	$	36,419		68	%
Spinal implant		13,200		28	%		17,203		32	%
Other revenue		144		0	%		319		0	%
Total revenue	$	47,718		100	%	$	53,941		100	%

Performance Obligations

Contract Assets and Liabilities

Research and Development

Research and Development

Research and development costs, which are principally related to internal costs for the development of new products, are expensed as incurred.

Net Loss Per Share

Net Loss Per Share

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The following table sets forth by level, within the fair value hierarchy, our liabilities that are measured at fair value on a recurring basis.

Warrant derivative liability (in thousands):

	As of September 30, 2019		As of December 31, 2018
Level 1		—		—
Level 2		—		—
Level 3	$	17	$	10

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Business Description, Basis of Presentation and Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Summary of Revenues from Product Lines

The following table presents revenues from these product lines for the three and nine months ended September 30, 2019 and 2018 (in thousands):

	Three Months Ended		Percentage of			Three Months Ended		Percentage of
	September 30, 2019		Total Revenue			September 30, 2018		Total Revenue
Orthobiologics	$	11,342		72	%	$	11,507		67	%
Spinal implant		4,349		28	%		5,632		33	%
Other revenue		30		0	%		127		0	%
Total revenue	$	15,721		100	%	$	17,266		100	%

	Nine Months Ended		Percentage of			Nine Months Ended		Percentage of
	September 30, 2019		Total Revenue			September 30, 2018		Total Revenue
Orthobiologics	$	34,374		72	%	$	36,419		68	%
Spinal implant		13,200		28	%		17,203		32	%
Other revenue		144		0	%		319		0	%
Total revenue	$	47,718		100	%	$	53,941		100	%

Schedule of Assets and Liabilities Measured on Recurring Basis

The following table sets forth by level, within the fair value hierarchy, our liabilities that are measured at fair value on a recurring basis.

Warrant derivative liability (in thousands):

	As of September 30, 2019		As of December 31, 2018
Level 1		—		—
Level 2		—		—
Level 3	$	17	$	10

Inventories (Tables)

9 Months Ended

Sep. 30, 2019

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories consist of the following (in thousands):

	September 30, 2019			December 31, 2018
Raw materials	$	3,738		$	3,519
Work in process		1,501			949
Finished goods		23,270			25,235
Gross inventories		28,509			29,703
Reserve for obsolescence		(12,484	)		(12,402	)
Total	$	16,025		$	17,301

Property and Equipment, Net (Tables)

9 Months Ended

Sep. 30, 2019

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment, Net

Property and equipment, net are as follows (in thousands):

	September 30, 2019			December 31, 2018
Equipment	$	4,140		$	4,145
Computer equipment		455			481
Computer software		570			570
Furniture and fixtures		99			164
Leasehold improvements		3,979			3,941
Vehicles		10			10
Surgical instruments		10,872			10,772
Total cost		20,125			20,083
Less: accumulated depreciation		(15,057	)		(12,909	)
Property and equipment, net	$	5,068		$	7,174

Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

The following table sets forth information regarding intangible assets (in thousands):

	September 30, 2019			December 31, 2018
Patents	$	847		$	847
Accumulated amortization		(318	)		(274	)
Intangible assets, net	$	529		$	573

Schedule of Estimated Amortization Expense for Intangible Assets

The following is a summary of estimated future amortization expense for intangible assets as of September 30, 2019 (in thousands):

Remainder of 2019	$	14
2020		56
2021		55
2022		54
2023		52
Thereafter		298
Total	$	529

Debt (Tables)

9 Months Ended

Sep. 30, 2019

Debt Disclosure [Abstract]

Schedule of Long-term Debt

Long-term debt consists of the following (in thousands):

	September 30, 2019			December 31, 2018
Amounts due under Second Amended and Restated Credit Agreement	$	72,657		$	—
Amounts due under Prior Credit Agreement		—			55,787
PIK interest payable related to Credit Agreements		2,172			27,178
Plus: 2% exit fee on Prior Credit Agreement		266			254
Gross long-term debt		75,095			83,219
Less: discount on Credit Agreements		—			(5,114	)
Less: total debt issuance costs on Credit Agreements		(110	)		(166	)
Long-term debt, less issuance costs	$	74,985		$	77,939

Schedule of Maturities Due on Debt

The following is a summary of maturities due on the long-term debt as of September 30, 2019 (in thousands):

Remainder of 2019	$	—
2020		—
2021		75,095
2022		—
2023		—
Thereafter		—
Total	$	75,095

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2019

Share-based Payment Arrangement [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity

Stock option activity, including options granted under the 2018 Plan, the Prior Plan, and the Non-Plan Grants, was as follows:

	2019							2018
	Shares			Weighted Average Exercise Price Per Share		Weighted Average Fair Value at Grant Date Per Share		Shares			Weighted Average Exercise Price Per Share		Weighted Average Fair Value at Grant Date Per Share
Outstanding at January 1		496,958		$	9.90	$	6.62		67,465		$	71.03	$	36.85
Granted		179,590		$	2.47	$	2.02		410,770		$	5.71	$	3.91
Cancelled or expired		(448,416	)	$	5.51	$	4.21		(33,002	)	$	53.23	$	36.42
Outstanding at September 30		228,132		$	12.51	$	7.64		445,233		$	12.09	$	6.49
Exercisable at September 30		25,464		$	89.03	$	49.36		34,463		$	135.23	$	67.26

Schedule of Assumptions of Stock Option Granted

	Nine Months Ended
	September 30,
	2019			2018
Risk free interest rate		2.2	%		2.9	%
Dividend yield		0	%		0	%
Expected term		8.3 years			10 years
Expected volatility		92	%		90	%

Warrants (Tables)

9 Months Ended

Sep. 30, 2019

Warrants and Rights Note Disclosure [Abstract]

Schedule of Warrant Activity

Outstanding at January 1, 2019	1,710,609	$	7.33
Issued	1,200,000		0.01
Expired	—		—
Outstanding at September 30, 2019	2,910,609	$	4.31

Schedule of Warrant Valuation Assumptions

The estimated fair value was derived using a valuation model with the following weighted-average assumptions:

	Nine Months Ended September 30,
	2019			2018
Value of underlying common stock (per share)	$	2.84		$	3.85
Risk free interest rate		1.7	%		2.10	%
Expected term in years		3.0			3.9
Volatility		85	%		62	%
Dividend yield		0	%		0	%

Schedule of Warrants Activities Used in Derivative Liability

The following table summarizes our activities related to warrants accounted for as a derivative liability for the nine months ended September 30, 2019 and 2018:

	2019		2018
Balance at January 1,		87,509		93,759
Derivative warrants expired		—		(6,250	)
Balance at September 30,		87,509		87,509

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

Schedule of Right-of-use Assets and Lease Liability

Present Value of Long-term Leases

(in thousands):	September 30, 2019
Right-of-use assets, net	$	2,198

Current portion of lease liability		387
Lease liability, less current portion		1,827
Total lease liability	$	2,214

Schedule of Future Minimum Rental Payments for Operating Leases

Future minimum payments for the next five years and thereafter as of September 30, 2019 under these long-term operating leases are as follows (in thousands):

Remainder of 2019	$	125
2020		501
2021		507
2022		521
2023		489
Thereafter		404
Total future minimum lease payments		2,547
Less amount representing interest		(333	)
Present value of obligations under operating leases		2,214
Less current portion		(387	)
Long-term operating lease obligations	$	1,827

Schedule of Future Minimum Lease Payments for Financing Leases

Future minimum payments for the next five years and thereafter as of September 30, 2019 under financing leases for equipment are as follows (in thousands):

Remainder of 2019	$	53
2020		205
2021		—
2022		—
2023		—
Thereafter		—
Total future minimum lease payments		258
Less amount representing interest		(23	)
Present value of obligations under financing leases		235
Less current portion		(229	)
Long-term financing lease obligations	$	6

Supplemental Disclosure of Cash Flow Information (Tables)

9 Months Ended

Sep. 30, 2019

Supplemental Cash Flow Elements [Abstract]

Schedule of Supplemental Cash Flow Information

Supplemental cash flow information is as follows (in thousands):

	Nine Months Ended
	September 30,
	2019		2018
Supplemental disclosure of cash flow information
Cash paid during the period for:
Interest	$	47	$	170
Non-cash activities:
Issuance of capital leases	$	—	$	84
Lease liability from right-of-use assets	$	2,296	$	—
Interest converted into common stock	$	—	$	556
Conversion of convertible debt to equity	$	—	$	71,865
Convertible PIK interest	$	—	$	4,764
Conversion of interest related to the Credit Facility to long-term debt	$	—	$	7,977
Write-off of convertible debt issuance cost	$	—	$	1,012
Transfer of inventory to property and equipment	$	—	$	448
Extinguishment of Prior Credit Agreement (including debt issuance costs)	$	79,624	$	—
Write-off of Prior Credit Agreement debt issuance costs and existing ROS fees	$	307	$	—
Recognition of Second Amended and Restated Credit Agreement	$	72,657	$	—
Recognition of 2019 Warrants	$	9	$	—
Debt discount	$	—	$	5,114

Segment and Geographic Information (Tables)

9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Schedule of Revenues by Geographic Region

Total revenue by major geographic area is as follows (in thousands):

	Three Months Ended September 30,
	2019		2018
United States	$	15,097	$	16,496
Rest of world		624		770
Total revenue	$	15,721	$	17,266

	Nine Months Ended September 30,
	2019		2018
United States	$	45,781	$	51,288
Rest of world		1,937		2,653
Total revenue	$	47,718	$	53,941

Business Description, Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)						3 Months Ended			9 Months Ended
	May 18, 2018 USD ($) $ / shares shares	Apr. 27, 2018 USD ($) $ / shares shares	Feb. 14, 2018 USD ($) $ / shares shares	Feb. 13, 2018 shares	Jan. 17, 2018 USD ($) $ / shares shares	Sep. 30, 2019 USD ($) shares	Sep. 30, 2018 shares	Mar. 31, 2018	Sep. 30, 2019 USD ($) Segment shares	Sep. 30, 2018 USD ($) shares	Dec. 31, 2018 USD ($) shares
Reverse stock split, description			Upon the effectiveness of the Reverse Stock Split, every 12 shares of our issued and outstanding common stock automatically converted into one share of common stock, without any change in the par value per share.	1-for-12 reverse split
Debt conversion, converted instrument, amount \| $										$ 71,865,000
Stock issued during period, shares, new issues	129
Shares issued, price per share \| $ / shares	$ 0.0869816
Stock issued during period, value, new issues \| $	$ 900									$ 79,199,000
Common stock, shares authorized						50,000,000			50,000,000		50,000,000
Preferred stock, shares authorized						10,000,000			10,000,000		10,000,000
Description of royalty opportunities			(i) issue new securities; (ii) incur over $0.25 million of debt in a fiscal year; (iii) sell or transfer over $0.25 million of our assets or businesses or our subsidiaries in a fiscal year; (iv) acquire over $0.25 million of assets or properties in a fiscal year; (v) make capital expenditures over $0.125 million individually, or $1.5 million in the aggregate during a fiscal year; (vi) approve our annual budget; (vii) hire or terminate our chief executive officer; (viii) appoint or remove the chairperson of the Board; and (ix) make, loans to, make investments in, or purchase, or permit any subsidiary to purchase, any stock or other securities in another entity in excess of $0.25 million in a fiscal year.
Ownership interest percentage description									(a) upon the mutual written agreement of all the parties, (b) upon written notice of the Company or an Investor, if such Investor's ownership percentage of our then outstanding common stock is less than 10%, or (c) upon written notice by the Investors. PWPI and PWIMF's right to purchase from us a pro rata amount of any new securities will also terminate at such time as their aggregate ownership percentage of our then outstanding common stock is less than 8.5%.
Number of reportable segments \| Segment									1
Impairment of long-lived assets \| $
Goodwill impairment charge \| $
Contract assets \| $
Contract liabilities \| $
Antidilutive securities excluded from computation of earnings per share, amount						3,313,953	2,156,882		3,313,953	2,156,882
Accounts Receivable [Member]
Concentration risk percentage									10.00%
Securities Purchase Agreement [Member]
Stock issued during period, shares, new issues			945,819
Shares issued, price per share \| $ / shares			$ 7.20
Stock issued during period, value, new issues \| $			$ 6,800,000
Before Reverse Stock Split [Member]
Common stock, shares authorized				95,000,000
Preferred stock, shares authorized				5,000,000
After Reverse Stock Split Member]
Common stock, shares authorized				50,000,000
Preferred stock, shares authorized				10,000,000
Maximum [Member]
Stock issued during period, shares, new issues	1,137,515
Minimum [Member]
Outstanding common stock in percentage			40.00%
Restructuring Agreement [Member]
Stock issued during period, shares, new issues		129
Shares issued, price per share \| $ / shares		$ 7.20
Rights offering expired		Jun. 18, 2018
Stock issued during period, value, new issues \| $		$ 900
Restructuring Agreement [Member] \| Maximum [Member]
Stock issued during period, shares, new issues		1,137,515
2017 Notes [Member]
Debt conversion, converted instrument, shares issued					189,645
6.00% Convertible Senior Unsecured Notes [Member]
Debt instrument, stated percentage			6.00%
Debt instrument due date description			Convertible senior unsecured notes due 2021		Convertible senior unsecured notes due 2021			All of the outstanding 6.00% convertible senior unsecured notes due 2021
Debt instrument, conversion price per share \| $ / shares			$ 7.20
Debt conversion, converted instrument, shares issued			10,401,309		189,645
Debt conversion, converted instrument, amount \| $			$ 70,300,000		$ 1,600,000
Debt instrument, convertible, conversion ratio			138.8889
Debt instrument, principal amount per share conversion \| $ / shares			$ 1,000
6.00% Convertible Senior Unsecured Notes [Member] \| OrbiMed Royalty Opportunities II, LP [Member]
Non-controlling interest, ownership percentage by parent			70.00%
6.00% Convertible Senior Unsecured Notes [Member] \| 2017 Notes [Member]
Debt instrument, stated percentage					6.00%
Debt instrument due date description					Convertible senior unsecured notes due 2021
Debt instrument, conversion price per share \| $ / shares					$ 9.11

Business Description, Basis of Presentation and Summary of Significant Accounting Policies - Summary of Revenues from Product Lines (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Total revenue	$ 15,721	$ 17,266	$ 47,718	$ 53,941
Percentage of total revenue	100.00%	100.00%	100.00%	100.00%
Orthobiologics [Member]
Total revenue	$ 11,342	$ 11,507	$ 34,374	$ 36,419
Percentage of total revenue	72.00%	67.00%	72.00%	68.00%
Spinal Implant [Member]
Total revenue	$ 4,349	$ 5,632	$ 13,200	$ 17,203
Percentage of total revenue	28.00%	33.00%	28.00%	32.00%
Other Revenue [Member]
Total revenue	$ 30	$ 127	$ 144	$ 319
Percentage of total revenue	0.00%	0.00%	0.00%	0.00%

Business Description, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Warrant derivative liability	$ 17	$ 10
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Measurements, Recurring [Member]
Warrant derivative liability
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Measurements, Recurring [Member]
Warrant derivative liability
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Measurements, Recurring [Member]
Warrant derivative liability	$ 17	$ 10

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 3,738	$ 3,519
Work in process	1,501	949
Finished goods	23,270	25,235
Gross inventories	28,509	29,703
Reserve for obsolescence	(12,484)	(12,402)
Total	$ 16,025	$ 17,301

Property and Equipment, Net (Details Narrative) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 2,300	$ 2,400
Financial leased assets, gross	1,500
Financial leases, lessee balance sheet, assets by major class, accumulated depreciation	$ 900

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Total cost	$ 20,125	$ 20,083
Less: accumulated depreciation	(15,057)	(12,909)
Property and equipment, net	5,068	7,174
Equipment [Member]
Property, Plant and Equipment [Line Items]
Total cost	4,140	4,145
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total cost	455	481
Computer Software [Member]
Property, Plant and Equipment [Line Items]
Total cost	570	570
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total cost	99	164
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total cost	3,979	3,941
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Total cost	10	10
Surgical Instruments [Member]
Property, Plant and Equipment [Line Items]
Total cost	$ 10,872	$ 10,772

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 847	$ 847
Accumulated amortization	(318)	(274)
Intangible assets, net	$ 529	$ 573

Intangible Assets - Schedule of Estimated Amortization Expense for Intangible Assets (Details) $ in Thousands	Sep. 30, 2019 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2019	$ 14
2020	56
2021	55
2022	54
2023	52
Thereafter	298
Total	$ 529

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Wages/commissions payable	$ 3,849	$ 3,332
Other accrued liabilities	2,347	1,818
Accrued liabilities	$ 6,196	$ 5,150

Debt (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands					3 Months Ended		9 Months Ended
	Mar. 29, 2019	Sep. 17, 2018	Feb. 14, 2018	Jan. 17, 2018	Mar. 31, 2019	Mar. 31, 2018	Sep. 30, 2019	Apr. 02, 2019	Dec. 31, 2018
Debt instrument, basis spread on variable rate							13.45%
Debt instrument description		The Optional PIK Interest (as such term is defined in the Prior Credit Agreement) was decreased from 15% plus the LIBO Rate (as such term is defined in the Amended and Restated Credit Agreement) to 10% plus the LIBO Rate, with a 2.3125% floor; a LIBO Rate floor of 2.3125% was added
Issuance of warrants to purchase a common stock		1,200,000
Exercise price of warrants		$ 0.01					$ 4.31		$ 7.33
Warrants expiration date		Aug. 01, 2028
Long-term debt							$ 74,985		$ 77,939
2019 Warrants [Member] \| Investors [Member]
Issuance of warrants to purchase a common stock								1,200,000
Exercise price of warrants								$ 0.01
Warrants expiration date								Apr. 01, 2029
Second Amended and Restated Credit Agreement [Member]
Debt instrument description	No interest will accrue on the Loans under the Second Amended and Restated Credit Agreement from and after January 1, 2019 until March 31, 2020; beginning April 1, 2020 through the maturity date of the Second Amended and Restated Credit Agreement, interest payable in cash will accrue on the Loans under the Credit Agreement at a rate per annum equal to the sum of (a) 10.00% plus (b) the higher of (x) the LIBO Rate (as such term is defined in the Second Amended and Restated Credit Agreement) and (y) 2.3125%; the maturity date of the Loans is March 31, 2021;
Debt instrument face amount	$ 2,200						55,800
Debt instrument maturity date	Mar. 31, 2021
Long-term debt					$ 72,700		75,000
Increase in additional paid-in capital					$ 7,300
Accrued PIK interest							$ 27,200
New effective interest rate	13.19%
Second Amended and Restated Credit Agreement [Member] \| Forecast [Member]
Cash balance	$ 1,500
Second Amended and Restated Credit Agreement [Member] \| Investors [Member]
Debt instrument face amount	$ 10,000
Maximum [Member]
Credit facility percentage		2.00%
Minimum [Member]
Credit facility percentage		1.00%
Twenty-Third Amendment to Amended and Restated Credit Agreement [Member] \| Through December 31, 2018 [Member]
Debt instrument, basis spread on variable rate			12.00%
Debt instrument interest rate portion payable in cash			10.00%
Twenty-Third Amendment to Amended and Restated Credit Agreement [Member] \| January 1, 2019 through September 30, 2019 [Member]
Debt instrument, basis spread on variable rate			15.00%
Debt instrument interest rate portion payable in cash			10.00%
Twenty-Third Amendment to Amended and Restated Credit Agreement [Member] \| July 1, 2019 through the maturity date [Member]
Debt instrument, basis spread on variable rate			10.00%
Debt instrument, fee percentage			1.00%
6.00% Convertible Senior Unsecured Notes [Member]
Debt instrument due date description			Convertible senior unsecured notes due 2021	Convertible senior unsecured notes due 2021		All of the outstanding 6.00% convertible senior unsecured notes due 2021

Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
Amounts due under Second Amended and Restated Credit Agreement	$ 72,657
Amounts due under Prior Credit Agreement		55,787
PIK interest payable related to Credit Agreements	2,172	27,178
Plus: 2% exit fee on Prior Credit Agreement	266	254
Gross long-term debt	75,095	83,219
Less: discount on Credit Agreements		(5,114)
Less: total debt issuance costs on Credit Agreements	(110)	(166)
Long-term debt, less issuance costs	$ 74,985	$ 77,939

Debt - Schedule of Maturities Due on Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
Remainder of 2019
2020
2021	75,095
2022
2023
Thereafter
Long-term debt, less issuance costs	$ 74,985	$ 77,939

Equity (Details Narrative) - USD ($)				3 Months Ended		9 Months Ended
Equity (Details Narrative) - USD ($)	May 18, 2018	Feb. 14, 2018	Jan. 17, 2018	Sep. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Oct. 30, 2019	Dec. 31, 2018
Schedule of Equity Method Investments [Line Items]
Common stock, shares authorized						50,000,000			50,000,000
Debt conversion of convertible debt							$ 71,865,000
Stock issued during period, shares, new issues	129
Shares issued, price per share	$ 0.0869816
Stock issued during period, value, new issues	$ 900						$ 79,199,000
Share price	$ 7.20
Right offering expired date	Jun. 18, 2018
Private Placement SPA [Member]
Schedule of Equity Method Investments [Line Items]
Stock issued during period, shares, new issues		945,819
Shares issued, price per share		$ 7.20
Stock issued during period, value, new issues		$ 6,800,000
6.00% Convertible Senior Unsecured Notes [Member]
Schedule of Equity Method Investments [Line Items]
Debt instrument due date description		Convertible senior unsecured notes due 2021	Convertible senior unsecured notes due 2021		All of the outstanding 6.00% convertible senior unsecured notes due 2021
Debt conversion of convertible debt		$ 70,300,000	$ 1,600,000
Debt conversion, converted instrument, shares issued		10,401,309	189,645
Additional debt principal amount		$ 70,300,000
Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Stock issued during period, shares, new issues	1,137,515
Charter Amendment [Member] \| Subsequent Event [Member]
Schedule of Equity Method Investments [Line Items]
Common stock, shares authorized								75,000,000

Stock-Based Compensation (Details Narrative) - USD ($) $ in Thousands		9 Months Ended
	Aug. 01, 2018	Sep. 30, 2019	Sep. 30, 2018	Oct. 07, 2019
Options granted to purchase shares		179,590	410,770
Intrinsic value of options outstanding		$ 66
Employees and Directors [Member]
Allocated share-based compensation expense		$ 300	$ 600
Employment Agreement [Member] \| Subsequent Event [Member]
Number of shares available for issuance				329,044
2018 Equity Incentive Plan [Member]
Number of shares available for issuance	2,807,747
Term of plan, description	The 2018 Plan became effective immediately upon initial approval of the plan by our stockholders on August 1, 2018 and will expire on July 31, 2028, unless terminated earlier.
Number of common stock shares remaining available	1,742,387
Options granted to purchase shares		210,360
Restricted stock granted during period, shares		13,021
Options to purchase shares of common stock forfeited and cancelled		420,000
2018 Equity Incentive Plan [Member] \| Restricted Stock Units (RSUs) [Member]
Options granted to purchase shares		129,204
2018 Equity Incentive Plan [Member] \| Maximum [Member]
Number of shares available for issuance	1,500,000
Xtant Medical Equity Incentive Plan [Member]
Options granted to purchase shares		17,772
Restricted stock granted during period, shares		23,438
Xtant Medical Equity Incentive Plan [Member] \| Termination of Employment of Optionees [Member]
Options to purchase shares of common stock forfeited and cancelled		3,416
Xtant Medical Equity Incentive Plan [Member] \| Termination of Service of Director [Member]
Options to purchase shares of common stock forfeited and cancelled		10,417
Non-Plan Grants [Member]
Options to purchase shares of common stock forfeited and cancelled		25,000

Stock-Based Compensation - Schedule of Share-based Compensation, Stock Options, Activity (Details) - Equity Option [Member] - $ / shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Shares Outstanding, Beginning Balance	496,958	67,465
Shares Granted	179,590	410,770
Shares Cancelled or Expired	(448,416)	(33,002)
Shares Outstanding, Ending Balance	228,132	445,233
Shares Exercisable, Ending Balance	25,464	34,463
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 9.90	$ 71.03
Weighted Average Exercise Price, Granted	2.47	5.71
Weighted Average Exercise Price, Cancelled or Expired	5.51	53.23
Weighted Average Exercise Price, Outstanding Ending Balance	12.51	12.09
Weighted Average Exercise Price, Exercisable Ending Balance	89.03	135.23
Weighted Average Fair Value at Grant Date, Outstanding Beginning Balance	6.62	36.85
Weighted Average Fair Value at Grant Date, Granted	2.02	3.91
Weighted Average Fair Value at Grant Date, Cancelled or Expired	4.21	36.42
Weighted Average Fair Value at Grant Date, Outstanding Ending Balance	7.64	6.49
Weighted Average Fair Value at Grant Date, Exercisable, Ending Balance	$ 49.36	$ 67.26

Stock-Based Compensation - Schedule of Assumptions of Stock Option Granted (Details)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Stock-based Compensation - Schedule Of Assumptions Of Stock Option Granted
Risk free interest rate	2.20%	2.90%
Dividend yield	0.00%	0.00%
Expected term	8 years 3 months 19 days	10 years
Expected volatility	92.00%	90.00%

Warrants (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2019	Apr. 02, 2019	Dec. 31, 2018	Sep. 17, 2018
Class of Warrant or Right [Line Items]
Issuance of warrants to purchase a common stock				1,200,000
Exercise price of warrants	$ 4.31		$ 7.33	$ 0.01
Warrants expiration date				Aug. 01, 2028
Number of outstanding common stock warrants	2,910,609		1,710,609
Unrealized loss on warranty derivative liability	$ 8
2019 Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value of warrants	$ 9
2019 Warrants [Member] \| Investors [Member]
Class of Warrant or Right [Line Items]
Issuance of warrants to purchase a common stock		1,200,000
Exercise price of warrants		$ 0.01
Warrants expiration date		Apr. 01, 2029
Number of outstanding common stock warrants		2,910,609

Warrants - Schedule of Warrant Activity (Details)	9 Months Ended
Warrants - Schedule of Warrant Activity (Details)	Sep. 30, 2019 $ / shares shares
Warrants and Rights Note Disclosure [Abstract]
Common Stock Warrants Outstanding, Beginning Balance	1,710,609
Common Stock Warrants, Issued	1,200,000
Common Stock Warrants, Expired
Common Stock Warrants Outstanding, Ending Balance	2,910,609
Weighted Average Exercise Price Outstanding Beginning Balance \| $ / shares	$ 7.33
Weighted Average Exercise Price, Issued	0.01
Weighted Average Exercise Price, Expired \| $ / shares
Weighted Average Exercise Price Outstanding Ending Balance \| $ / shares	$ 4.31

Warrants - Schedule of Warrant Valuation Assumptions (Details)	9 Months Ended
	Sep. 30, 2019 $ / shares	Sep. 30, 2018 $ / shares	May 18, 2018 $ / shares
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Value of underlying common stock (per share)			$ 0.0869816
Warrant [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Value of underlying common stock (per share)	$ 2.84	$ 3.85
Warrants and rights outstanding, measurement Input, expected term (In years)	3 years	3 years 10 months 25 days
Warrant [Member] \| Risk Free Interest Rate [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Warrants and rights outstanding, measurement Input	1.7	2.10
Warrant [Member] \| Volatility [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Warrants and rights outstanding, measurement Input	85	62
Warrant [Member] \| Dividend Yield [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Warrants and rights outstanding, measurement Input	0	0

Warrants - Schedule of Warrants Activities Used in Derivative Liability (Details) - shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Class of Warrant or Right [Line Items]
Common Stock Warrants Outstanding, Beginning Balance	1,710,609
Common Stock Warrants Outstanding, Ending Balance	2,910,609
Warrant [Member]
Class of Warrant or Right [Line Items]
Common Stock Warrants Outstanding, Beginning Balance	87,509	93,759
Derivative warrants expired		(6,250)
Common Stock Warrants Outstanding, Ending Balance	87,509	87,509

Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Operating lease expiration description	Expiration dates between 2019 and 2025
Security deposits	$ 49
Operating lease weighted-average remaining lease term	5 years
Operating lease weighted-average discount rate	5.20%
Rent expense	$ 400	$ 900
Minimum [Member]
Lessee leasing arrangements operating leases term of each option to extend	5 years
Maximum [Member]
Lessee leasing arrangements operating leases term of each option to extend	10 years

Commitments and Contingencies - Schedule of Right-of-use Assets and Lease Liability (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Commitments And Contingencies - Schedule Of Right-of-use Assets And Lease Liability
Right-of-use assets, net	$ 2,198
Current portion of lease liability	387
Lease liability, less current portion	1,827
Total lease liability	$ 2,214

Commitments and Contingencies - Schedule of Future Minimum Rental Payments for Operating Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Remainder of 2019	$ 125
2020	501
2021	507
2022	521
2023	489
Thereafter	404
Total future minimum lease payments	2,547
Less amount representing interest	(333)
Present value of obligations under operating leases	2,214
Less current portion	(387)
Long-term operating lease obligations	$ 1,827

Commitments and Contingencies - Schedule of Future Minimum Lease Payments for Financing Leases (Details) $ in Thousands	Sep. 30, 2019 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Remainder of 2019	$ 53
2020	205
2021
2022
2023
Thereafter
Total future minimum lease payments	258
Less amount representing interest	(23)
Present value of obligations under financing leases	235
Less current portion	(229)
Long-term financing lease obligations	$ 6

Supplemental Disclosure of Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Supplemental Cash Flow Elements [Abstract]
Interest	$ 47,000	$ 170,000
Issuance of capital leases		84,000
Lease liability from right-of-use assets	2,296,000
Interest converted into common stock		556,000
Conversion of convertible debt to equity		71,865,000
Convertible PIK interest		4,764,000
Conversion of interest related to the Credit Facility to long-term debt		7,977,000
Write-off of convertible debt issuance cost		1,012,000
Transfer of inventory to property and equipment		448,000
Extinguishment of Prior Credit Agreement (including debt issuance costs)	79,624,000
Write-off of Prior Credit Agreement debt issuance costs and existing ROS fees	307,000
Recognition of Second Amended and Restated Credit Agreement	72,657,000
Recognition of 2019 Warrants	9,000
Debt discount		$ 5,114,000

Related Party Transactions (Details Narrative) - USD ($) $ in Thousands		3 Months Ended	4 Months Ended	9 Months Ended
	Apr. 05, 2019	Sep. 30, 2019	Jul. 31, 2019	Sep. 30, 2019
Related Party Transaction [Line Items]
Operating lease description				Expiration dates between 2019 and 2025
Sublease Agreement [Member] \| Cardialen, Inc., [Member]
Related Party Transaction [Line Items]
Operating lease description	Portion of Cardialen's office space commencing April 2019, on a month-to-month basis until January 2024, unless terminated earlier upon notice of 60 days.
Sublease rent expense			$ 2,100
Monthly rental expenses		$ 1,260
Investors [Member]
Related Party Transaction [Line Items]
Ownership percentage		70.00%		70.00%

Segment and Geographic Information (Details Narrative)	9 Months Ended
Segment and Geographic Information (Details Narrative)	Sep. 30, 2019	Sep. 30, 2018
Geographic Concentration Risk [Member] \| United States [Member] \| Sales Revenue, Net [Member]
Concentration risk, percentage	96.00%	95.00%

Segment and Geographic Information - Schedule of Revenues by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Total revenue	$ 15,721	$ 17,266	$ 47,718	$ 53,941
United States [Member]
Total revenue	15,097	16,496	45,781	51,288
Rest of World [Member]
Total revenue	$ 624	$ 770	$ 1,937	$ 2,653

Income Taxes (Details Narrative) - USD ($)	9 Months Ended
Income Taxes (Details Narrative) - USD ($)	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Interest or penalties related to income taxes